TTOO Capital Stock vs Total Stockholder Equity Analysis
TTOO Stock | USD 4.39 0.69 18.65% |
T2 Biosystms financial indicator trend analysis is much more than just breaking down T2 Biosystms prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether T2 Biosystms is a good investment. Please check the relationship between T2 Biosystms Capital Stock and its Total Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
Capital Stock vs Total Stockholder Equity
Capital Stock vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of T2 Biosystms Capital Stock account and Total Stockholder Equity. At this time, the significance of the direction appears to have almost no relationship.
The correlation between T2 Biosystms' Capital Stock and Total Stockholder Equity is 0.17. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of T2 Biosystms, assuming nothing else is changed. The correlation between historical values of T2 Biosystms' Capital Stock and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of T2 Biosystms are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Capital Stock i.e., T2 Biosystms' Capital Stock and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.17 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from T2 Biosystms' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into T2 Biosystms current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.As of the 14th of May 2024, Enterprise Value is likely to grow to about 75.5 M, while Selling General Administrative is likely to drop about 26 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 6.6M | 6.1M | 5.3M | 4.9M | Depreciation And Amortization | 318K | 39K | 859K | 843.9K |
T2 Biosystms fundamental ratios Correlations
Click cells to compare fundamentals
T2 Biosystms Account Relationship Matchups
High Positive Relationship
High Negative Relationship
T2 Biosystms fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Short Long Term Debt Total | 44.8M | 55.8M | 57.1M | 59.2M | 49.5M | 42.0M | |
Other Current Liab | 13.6M | 6.4M | 7.2M | 7.7M | 11.5M | 7.1M | |
Total Current Liabilities | 60.6M | 9.8M | 11.7M | 10.5M | 56.2M | 59.0M | |
Total Stockholder Equity | (34.0M) | 8.7M | (12.9M) | (40.0M) | (28.0M) | (26.6M) | |
Other Liab | 46K | 4.8M | 4.6M | 4.9M | 5.6M | 5.9M | |
Property Plant And Equipment Net | 9.2M | 14.8M | 14.4M | 13.3M | 9.1M | 9.8M | |
Net Debt | 33.7M | 39.0M | 34.9M | 48.9M | 33.8M | 35.5M | |
Retained Earnings | (376.2M) | (423.0M) | (472.2M) | (534.5M) | (584.3M) | (555.1M) | |
Accounts Payable | 3.8M | 2.1M | 2.8M | 1.3M | 1.5M | 1.6M | |
Cash | 11.0M | 16.8M | 22.2M | 10.3M | 15.7M | 28.6M | |
Non Current Assets Total | 9.6M | 25.5M | 16.1M | 15.0M | 9.7M | 11.6M | |
Cash And Short Term Investments | 11.0M | 42.2M | 32.2M | 10.3M | 15.7M | 31.0M | |
Common Stock Total Equity | 36K | 44K | 51K | 147K | 169.1K | 177.5K | |
Common Stock Shares Outstanding | 9.1K | 24.3K | 31.8K | 51.0K | 2.6M | 2.7M | |
Liabilities And Stockholders Equity | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Non Current Liabilities Total | 1.9M | 60.6M | 61.8M | 63.9M | 6.7M | 6.3M | |
Other Current Assets | 1.4M | 2.7M | 3.1M | 2.6M | 3.2M | 1.7M | |
Other Stockholder Equity | 342.1M | 431.5M | 459.2M | 494.6M | 556.3M | 315.0M | |
Total Liab | 62.5M | 70.4M | 73.4M | 74.4M | 62.8M | 50.8M | |
Property Plant And Equipment Gross | 9.2M | 14.8M | 14.4M | 13.3M | 23.9M | 25.1M | |
Total Current Assets | 18.9M | 53.6M | 44.4M | 19.4M | 25.1M | 35.3M | |
Short Term Debt | 42.9M | 1.2M | 1.2M | 1.4M | 42.9M | 45.0M | |
Common Stock | 49K | 147K | 166K | 8K | 4K | 3.8K | |
Property Plant Equipment | 5.8M | 14.8M | 14.4M | 13.3M | 15.3M | 9.5M | |
Net Tangible Assets | (32.1M) | 8.7M | (12.9M) | (40.0M) | (36.0M) | (34.2M) | |
Current Deferred Revenue | 285K | 230K | 518K | 172K | 224K | 212.8K | |
Net Receivables | 2.8M | 5.1M | 5.1M | 2.2M | 1.4M | 2.2M | |
Retained Earnings Total Equity | (266.1M) | (317.2M) | (376.2M) | (423.0M) | (380.7M) | (399.7M) | |
Capital Surpluse | 267.4M | 328.5M | 342.1M | 431.5M | 496.3M | 308.8M | |
Inventory | 3.6M | 3.6M | 3.9M | 4.3M | 4.8M | 2.9M | |
Short Long Term Debt | 40.7M | 42.4M | 42.9M | 41.3M | 47.5M | 27.2M | |
Capital Lease Obligations | 3.9M | 10.5M | 9.4M | 9.6M | 8.2M | 6.1M |
Currently Active Assets on Macroaxis
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for TTOO Stock analysis
When running T2 Biosystms' price analysis, check to measure T2 Biosystms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy T2 Biosystms is operating at the current time. Most of T2 Biosystms' value examination focuses on studying past and present price action to predict the probability of T2 Biosystms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move T2 Biosystms' price. Additionally, you may evaluate how the addition of T2 Biosystms to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is T2 Biosystms' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 109.92 | Revenue Per Share 1.864 | Quarterly Revenue Growth (0.01) | Return On Assets (1.00) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.